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Abstract: [18F]FPEB is a positron emission tomography (PET) radiopharmaceutical used for imaging
the abundance and distribution of mGluR5 in the central nervous system (CNS). Efficient radiolabeling
of the aromatic ring of [18F]FPEB has been an ongoing challenge. Herein, five metal-free precursors
for the radiofluorination of [18F]FPEB were compared, namely, a chloro-, nitro-, sulfonium salt,
and two spirocyclic iodonium ylide (SCIDY) precursors bearing a cyclopentyl (SPI5) and a new
adamantyl (SPIAd) auxiliary. The chloro- and nitro-precursors resulted in a low radiochemical
yield (<10% RCY), whereas both SCIDY precursors and the sulfonium salt precursor produced
[18F]FPEB in the highest RCYs of 25% and 36%, respectively. Preliminary PET/CT imaging
studies with [18F]FPEB were conducted in a transgenic model of Alzheimer’s Disease (AD) using
B6C3-Tg(APPswe,PSEN1dE9)85Dbo/J (APP/PS1) mice, and data were compared with age-matched
wild-type (WT) B6C3F1/J control mice. In APP/PS1 mice, whole brain distribution at 5 min
post-injection showed a slightly higher uptake (SUV = 4.8 ± 0.4) than in age-matched controls
(SUV = 4.0 ± 0.2). Further studies to explore mGluR5 as an early biomarker for AD are underway.
Keywords: [18F]FPEB; mGluR5; positron emission tomography (PET); iodonium-ylide; Alzheimer’s
Disease (AD)
1. Introduction
L-Glutamate is the primary excitatory neurotransmitter at the majority of excitatory synapses in
the mammalian central nervous system (CNS). Signaling processes involving metabotropic glutamate
occur via membrane-bound G-protein coupled receptors (GPCRs) known as metabotropic glutamate
receptors (mGluRs). There are eight mGluR subtypes, of which the mGluR5 subtype is involved in the
excitatory signaling cascade of intracellular calcium release, playing a vital role in brain development,
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learning, memory, and in maintaining synaptic plasticity [1]. Changes in mGluR5 expression have been
identified in several neuropathological diseases and disorders including addiction, Parkinson’s disease,
post-traumatic stress disorder (PTSD), epilepsy, Huntington’s disease, and Alzheimer’s disease (AD),
making mGluR5 an attractive target for the development of new therapeutics and for monitoring the
progression of several CNS disease states [2–4]. Positron emission tomography (PET) serves as a highly
sensitive and non-invasive means of monitoring the changes in mGluR5 distribution and regulation
associated with pathophysiological conditions in the CNS [5,6]. [18F]3-Fluoro-5-[(pyridin-3-yl)ethynyl]
benzonitrile ([18F]FPEB) was developed as a mGluR5 PET ligand and is widely used in clinical
research [7,8].
The routine radiosynthesis of [18F]FPEB has traditionally been low yielding because nucleophilic
aromatic substitution by [18F]fluoride is not favored as the nitrile group is positioned meta to the
leaving group on the aromatic ring of the precursor. Furthermore, high temperature reactions are
generally required, leading to decomposition products and radiochemical impurities. [18F]FPEB is
commonly synthesized from a chloro- or nitro-precursor in low radiochemical yields (RCYs, <10%)
as shown in Table 1 (1 and 2, respectively). When initially reported by Merck Research Laboratories,
[18F]FPEB was prepared via a SNAr reaction of an aryl-chloro precursor (1) with labeled potassium
cryptand fluoride, [K222][18F], and K2CO3 as the base [9]. This reaction resulted in 5% RCY and
required microwave conditions. Like the majority of others, our development of [18F]FPEB for
human use was initiated with the commercially available nitro-precursor and a low RCY (4%) was
achieved [10]. Compound 3 is a boronic acid precursor and 4 is an arylstannane precursor that were
used in copper-mediated radiofluorinations to synthesize [18F]FPEB in decay-corrected automated
radiochemical conversions (RCC; not isolated) of 5% and 11% respectively [11,12]. Translating these
precursors for the radiopharmaceutical production of [18F]FPEB will be challenging as lower RCY
can be expected upon purification and formulation, while additional testing for residual metals will
be required.
In our efforts to optimize the efficiency of 18F-Csp2 bond formation, we discovered that the
use of harsh reaction conditions such as high temperatures and base concentrations resulted in the
increased formation of radiolabeled impurities over time. This included the hydrolyzed product
3-fluoro-5-(pyridin-2-ylethynyl)benzamide, which contributed to the low yields previously obtained
for both the chloro- and nitro-precursors [13]. Our development of spirocyclic iodonium ylide (SCIDY)
precursors for radiofluorination of non-activated aromatic rings [14] was successfully applied to the
synthesis of (5) as a novel precursor for [18F]FPEB [13,15]. The ylide precursor showed a ten-fold
increase in the radiochemical yield and a five-fold increase in molar activity (Am) of [18F]FPEB,
compared with our traditional SNAr reaction with the nitro-precursor [10], and was validated and
translated for human use [12,13].
The aim of this study was to compare the chloro- and nitro-precursors for [18F]FPEB, with
our first-generation SCIDY precursor (cyclopentyl auxiliary (5)) and new second-generation SCIDY
precursor (adamantyl auxiliary (7)) and a newly reported sulfonium salt precursor (6) for the routine
production of [18F]FPEB [16,17]. Only metal-free precursors were considered for this work to avoid the
need for additional quality control testing of residual metals in routine radiopharmaceutical production.
In light of our pilot PET imaging studies that showed increased [18F]FPEB binding in a patient with
early mild cognitive impairment [10], we also explored the use of [18F]FPEB to detect early changes in
mGluR5 expression in a transgenic murine model of AD.
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2. Results and Discussion
2.1. Radiosyntheses of [18F]FPEB with Five Different Precursors
The chloro-precursor (1) was synthesized following a literature procedure, with the modification
that conventional heating was used to drive the radiofluorination instead of the previously reported
microwave conditions [9]. In our hands, a maximum 3% RCC was observed by manual synthesis at
200 °C from a 10 min reaction. In light of the low radiofluorination conversion, this precursor was not
considered for automated radiosynthesis (Table 2, Entry I). While manual radiosynthesis of [18F]FPEB
via the commercially available nitro-precursor (2) showed an RCC based on radio-HPLC analysis of
33% (n = 3) at 150 ◦C for a reaction time of 5 min, upon automation and isolation, the highest RCY was
only 4% (Table 2, Entry II). This low RCY from the nitro-precursor is consistent with other reported
production yields [8,10,18,19]. Losses experienced when translated to an automated synthesis unit
may be attributed to transfer to tubing and reaction vessels. The low yielding reaction, together with
the presence of radiochemical and UV active impurities, observed by HPLC, led us to abandon the
optimization of [18F]FPEB radiosynthesis using the nitro-precursor and explore alternative precursors.
We recently showed that using the SCIDY chemistry with a cyclopentyl auxiliary (SPI5) (5) as
the precursor for [18F]FPEB production led to a five-fold increase in RCY and a three-fold increase in
molar activity (Am) compared to the nitro-precursor. The SCIDY precursor enabled the displacement
reaction with [18F]fluoride to be conducted at milder conditions (lower temperatures and shorter
times), thereby minimizing the formation of radiochemical impurities. [18F]FPEB synthesis via the
SCIDY SPI5 auxiliary precursor was conducted on a GE TRACERlab™ FX2 N automated synthesis
module. Varying temperatures and reaction times resulted in RCYs of [18F]FPEB ranging from 19% to
23% after HPLC purification and formulation (Table 2, Entry III). [18F]FPEB production was repeated
via the SPI5 precursor using the optimal conditions (100 ◦C, Et4NHCO3 as the base and a 5 min reaction
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time) which resulted in a RCY of 25% ± 2%, with a molar activity (Am) of = 37 ± 13 GBq/µmol (n = 3),
consistent with our previous reports [13,15].












I (1) K2CO3/K222 DMSO 200 10 N/A N/A
II (2) K2CO3/K222 DMSO 150 5 4 N/A
III (5)
Et4NHCO3 DMF 80 5 23 22
Et4NHCO3 DMF 80 10 19 54







Et4NHCO3 DMF 100 5 24 21
V (6)
Et4NHCO3 CH3CN 80 5 15 70
Et4NHCO3 CH3CN 100 5 26 168
KHCO3/K222 CH3CN 80 5 36 ± 6 * 77 ± 35 *
* n = 3.
These automated reaction conditions were then applied to a novel SCIDY precursor for [18F]FPEB
radiosynthesis, bearing an adamantyl-based auxiliary (SPIAd). Experimental and mechanistic studies
have shown that radiofluorination with the bulkier SPIAd auxiliary in SCIDY precursors can improve
the RCY compared to the SPI5 precursors in conventional nucleophilic aromatic substitution with
[18F]fluoride [17,20]. The SPIAd precursor (compound 7) also resulted in a 24% RCY for [18F]FPEB,
and is similar to that of the SPI5 precursor (Table 2, Entry IV). Our initial semi-preparative HPLC
purification conditions did not adequately separate the adamantyl precursor from [18F]FPEB, and
given the equivalent RCY between the two different SCIDY auxiliaries, optimization of the SPIAd
precursor reaction and/or HPLC conditions were not pursued (Supplementary Materials).
A recently reported precursor (6) based on a sulfonium salt was also applied to the manual
synthesis of [18F]FPEB and gave a reported 55% RCY [16]. Inspired by this report, we adapted the
radiochemistry precursor and methodology for automated radiofluorination with the GE TRACERlab™
FX2 N synthesis module. The reaction was conducted at varying temperatures (80 or 100 ◦C) for
5 min and with varying bases (Et4NHCO3 or KHCO3/K222) to establish optimal temperature and base
conditions, as summarized in Table 2, with the literature synthesis providing the highest yield [16].
Using [K222][18F] and the milder base (KHCO3) at 80 ◦C for 5 min (Table 2, Entry V), the sulfonium salt
precursor produced [18F]FPEB with a RCY of 36% ± 6% and Am = 77 ± 35 GBq/µmol (n = 3).
When considering which chemical route should be used to produce [18F]FPEB for clinical research,
many factors will impact this choice, including precursor availability, radiochemical yield, molar
activity, ease of automation and purification, etc. Although the nitro-precursor is currently the only
commercially available compound for [18F]FPEB production, the resulting yields are much lower than
the SCIDY and sulfonium salt precursors. The SPI5 auxiliary and the sulfonium salt precursors appear
to the be the best suited for routine radiopharmaceutical production of [18F]FPEB.
2.2. Small Animal PET/CT Imaging
mGluR5 has emerged as an imaging target in AD pathogenesis. It has been demonstrated that
soluble oligomeric amyloid-β (Aβo) induces an accumulation and over-stabilization of mGluR5,
and that Aβo up-regulates mGluR5, leading to an abnormal increase in the release of intracellular
Ca2+ [6,21–23]. Preliminary PET imaging data with [18F]FPEB showed increased brain uptake in
the transgenic model of AD versus the age-matched controls (10 month data shown in Figure 1).
Dynamic PET/CT imaging was carried out to investigate the difference in [18F]FPEB binding between
an established preclinical model of AD using 10 month old transgenic APP/PS1 mice and their
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age-matched wild-type (WT) controls. Axial, coronal, and sagittal images of the murine brains acquired
at 20 min post-injection of [18F]FPEB are presented in Figure 1A. A marked increased uptake of
radiotracer binding was observed in the brains of the transgenic mice compared with WT controls.
The time–activity curves revealed a similar initial peak uptake and brain penetration for both groups
of mice (Figure 1B). One minute after the time of injection (TOI), maximum uptake was observed in
both genotypes, (SUV > 6; whole brain VOI). By 10 min post-injection, a modest higher [18F]FPEB
retention was observed in the brain of transgenic mice (SUV = 4.8) versus WT controls (SUV = 4.0),
and as the tracer cleared from normal tissues, a significant difference (p < 0.05) was apparent at <5 min
post-injection. A comparison of the area under the curve (AUC) analysis (Figure 1C) over time for the
respected genotypes underscores the trends observed in the TACs.
 
Figure 1. (A) PET/CT images of [18F]FPEB 20 min post-injection in 10 month old APP/PS1 (transgenic)
mice and aged-matched wild-type (WT) B6C3F1/J (control) mice, n = 3/group. (B) Time–activity curve
for whole-brain. (C) Mean area under the curve (AUC).
In a pilot study, we found that patients with early mild cognitive impairment had an increased
brain uptake of [18F]FPEB, and that radiotracer uptake in the brain was reflective of increased mGluR5
density [10]. This observation supports the hypothesis that mGluR5 may be implicated in the early
stages of AD pathogenesis [24]. Consistent with this hypothesis and clinical research indication,
PET/CT imaging studies of [18F]FPEB uptake in a transgenic mouse model of AD also showed an
increased radiotracer uptake and retention in the brain of the APP/PS1 mice, compared with wild-type
controls. This preliminary work provides support that mGluR5 levels measured by [18F]FPEB are
potentially useful as an early biomarker of AD. Further [18F]FPEB imaging studies and biological
evaluations are underway including regional analysis of imaging data as well as ex vivo biodistribution
and autoradiography studies to evaluate this functional link between mGluR5 and AD.
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3. Materials and Methods
3.1. Materials and General Methods
Unless otherwise stated, all reagents were obtained from commercially available sources and
used without further purification. The identification of all radiochemical products was determined by
HPLC co-elution with an authentic non-radioactive standard. All RCC and RCY values are reported as
decay corrected, relative to starting [18F]fluoride (ca. 100 mCi). [18F]Fluoride was produced using a
Scanditronix MC17 cyclotron from enriched [18O]H2O through the 18O(p,n)18F reaction. Reverse-phase
high performance liquid chromatography (HPLC) was used to isolate and purify [18F]FPEB. Dynamic
PET/CT imaging experiments were conducted on a dedicated small-animal PET/CT scanner (eXplore
Vista-CT, Sedecal, Algete, Spain) equipped with VISTA-CT version 4.11 software.
3.1.1. General Chemistry and Radiochemistry Methods
Preparation of the chloro-precursor was performed as previously reported [9]. The nitro-precursor
(Lot No.: 20190401) and FPEB standard (Lot No.: 20130101) were purchased from ABX. Synthesis of the
sulfonium salt precursor and radiolabeling were performed as previously reported [16]. For manual
labeling, azeotropically dried potassium cryptand [18F]fluoride was dissolved in DMSO (3.0 mL), while
400 µL aliquots (typically 3–5 mCi) were used per reaction to dissolve the precursor in a 1 dram vial.
The reaction was heated at 150 ◦C for 5 min, then quenched with water and cooled for 3 min. Product
identity and radiochemical conversion were determined as the ratio of free [18F]fluoride to [18F]FPEB
as integrated by radio-HPLC. The manual radiolabeling of the chloro- (1) and nitro- (2) precursors
was performed as previously reported, with slight modification to the concentration and reaction time.
One milligram of 2 was dissolved in 0.4 mL [18F]fluoride in DMSO for 5 min instead of 1.5 mL for
15 min [8,18], and the chloro-reaction was conducted at high temperatures instead of under microwave
conditions [9]. For automated radiosyntheses, a GE TRACERlab™ FX2 N module with 2 and the SPI5
auxiliary SCIDY precursor (5) were performed as previously reported [13,15]. Flash chromatography
was performed on a Biotage Isolera One automated flash purification system. Biotage SNAP KP-Sil
50 g cartridges (45–60 micron) were used with a flow rate of 50 mL/min for gradient solvent systems.
Fractions were monitored and collected by UV absorbance using the internal UV detector set at 254
and 280 nm.
3.1.2. SCIDY-SPIAd Auxilary Synthesis and Characterization
The titled compound was prepared using a modified literature procedure [15]. Trifluoroacetic
acid (0.9 mL) was added to a solution of IPEB (120 mg, 0.36 mmol) in chloroform (0.12 mL). Oxone
(179 mg, 0.58 mmol) was added and the reaction mixture was stirred for 3 h, until full conversion of
starting materials was determined by TLC (SiO2 coated on polyethylene, 250 µm, with 100% EtOAc).
Volatile contents were then removed by rotary evaporation. The round bottom flask was covered
in foil and further dried under high vacuum for 5 h. The dried residue was suspended in ethanol
(1.5 mL) and (1r,3r,5r,7r)-spiro[adamantane-2,2′-[1,3]dioxane]-4′,6′-dione (67 mg, 0.54 mmol). SPIAd
was added followed by 10% Na2CO3(aq) (w/v, 1.5 mL, 0.33 M solution) in ~0.2 mL aliquots until the
pH of the reaction mixture was equal to pH 10. The reaction mixture was stirred for 5 h until full
conversion to the iodonium ylide was determined by TLC (SiO2 coated on polyethylene, 250 µm, with
10% EtOH in EtOAc, (1:9 mL v/v)). The reaction mixture was then diluted with water and extracted
with chloroform. The chloroform extracts were combined and washed with water (4 × 10 mL) and
brine (1 × 10 mL). The organic layer was dried with anhydrous MgSO4, filtered, and concentrated.
The final compound was purified by flash chromatography using a gradient 60% EtOAc in hexanes to
100% EtOAc to 5% methanol in EtOAc. Compound 7 (56 mg, 0.11 mmol) was isolated as an off-white
powder with a 41% yield.
1H NMR (500 MHz, dmso-d6) δ (ppm): 8.63 (dt, J = 4.7, 1.3 Hz, 1H), 8.31 (t, J = 1.5 Hz, 1H), 8.25 (t,
J = 1.6 Hz, 1H), 8.17 (t, J = 1.6 Hz, 1H), 7.89 (td, J = 7.7, 1.8 Hz, 1H), 7.73–7.67 (m, 1H), 7.47 (ddd, J = 7.7,
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4.8, 1.2 Hz, 1H), 2.35 (s, 2H), 1.93 (d, J = 12.3 Hz, 5H), 1.80–1.75 (m, 2H), 1.68–1.62 (m, 7H). 13C NMR
(126 MHz, dmso-d6) δ (ppm):163.10, 150.88, 141.60, 139.17, 137.54, 137.49, 136.20, 128.34, 125.05, 124.86,
117.02, 116.90, 114.37, 105.94, 92.58, 84.86, 59.00, 36.92, 35.31, 33.64, 26.38. HRMS (m/z): [M + Na]+
calcd. for C22H15IN2O4Na, 520.9974; found 520.9967.
3.1.3. General GE TRACERlab™ FX2 N Automated Synthesis Method
Cyclotron produced [18F]fluoride in enriched [18O]H2O was delivered to a GE TRACERlab™ FX2
N automated synthesis module. The [18F]fluoride was trapped on a HCO3− anion exchange cartridge
(Chromafix® [18F] SPE) without additional conditioning and eluted with one of the following base
mixtures: Et4NHCO3 in CH3CN/H2O, 4,7,13,16,21,24-hexaoxa-1,-10,diazabicyclo [8.8.8]hexacosane
(Kryptofix 222) and KHCO3 in CH3CN/H2O or Kryptofix 222 and K2CO3 in MeOH/H2O. The
[18F]fluoride was released from the cartridge and dried under nitrogen gas at 90 ◦C, followed by
azeotropic drying with acetonitrile under nitrogen gas at 110 ◦C, producing either dry [18F]Et4NF
or [18F]KF/K222 for radiofluorination. Automated radiosyntheses were carried out with precursors
2, 5, 6, and 7. Each precursor was dissolved in either DMSO, DMF, or CH3CN and eluted into the
reaction vial with the dry [18F]fluoride, where they were heated for the specified reaction time at
varying temperatures. The reactions were then cooled to room temperature and quenched with
HPLC buffer. The mixture was diluted with water and the crude reaction mixture was injected onto a
semi-preparative HPLC column. The eluent was monitored by UV, at a wavelength of 254 nm, and
radiochemical detectors in series. The desired radiochemical product was collected and formulated by
dilution with sterile water and loaded onto a C18 Sep-Pak cartridge (pre-activated with 10 mL EtOH,
followed by 10 mL H2O). The cartridge was washed with water to remove impurities and then eluted
with dehydrated EtOH, and finally, diluted with 0.9% sodium chloride. The final radiochemical yield
of this formulated product was determined (50–60 min; see ESI). Molar activity measurements were
carried out as described in [12].
3.1.4. Preliminary Small Animal PET/CT Imaging Studies
All animal experiments were conducted in compliance with Institutional Animal Care and Use
Committee (IACUC) guidelines and the Guide for the Care and Use of Laboratory Animals. Female
wild-type B6C3F1/J mice and female transgenic B6C3-Tg(APPswe,PSEN1dE9)85Dbo/J (APP/PS1; Stock
No.: 034829-JAX or MMRRC No. 034) mice were obtained from Jackson Laboratory (Bar Harbor, ME).
Mice were provided with food and water ad libitum. Mice were subjected to PET/CT imaging studies
after being aged to 10 months. Mice were administered formulations of [18F]FPEB (~3.1–14.0 MBq
[~84–378µCi], specific activity of 5 Ci/µmol, in 200µL sterile PBS, pH7.4,≤5% v/v EtOH) via intravenous
(i.v.) tail-vein injection using a catheter. Approximately 5 min prior to recording PET images, the
mice were anesthetized by inhalation of 3–4% isoflurane (Baxter Healthcare, Deerfield, IL)/oxygen
gas mixture, and a catheter was inserted into the tail-vein, with the mice then transferred to the
scanner bed and placed in the prone position. Anesthesia was maintained with 1–2% isoflurane/oxygen
gas mixture (flow rate ~5 L/min). Co-registered dynamic PET/CT images were recorded for a total
of 20 min post-injection radiotracer injection (n = 3 per group). List-mode data were acquired for
20 min per scan using a γ-ray energy window of 250–700 keV. To ensure that the activity bolus was
measured, PET/CT data acquisition was initiated 20 s prior to injecting the radioactivity. Data were
processed by 3-dimensional Fourier re-binning (3D-FORE), and images were reconstructed using
the 2-dimensional ordered-subset expectation maximum (2D-OSEM) algorithm. Image data were
normalized to correct for the non-uniformity of response of the PET, dead-time count losses, positron
branching ratio, and physical decay to the time of injection, but no attenuation, scatter, or partial-volume
averaging correction were applied. An empirically determined system calibration factor (in units of
Bq/cps) combined with the decay corrected administered activity and the animals’ weights were used
to parameterize image activity in terms of the standardized uptake value (SUV). Manually drawn
2-dimensional regions-of-interest (ROIs) or 3-dimensional volumes-of-interest (VOIs) were used to
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determine the maximum and mean SUV radiotracer uptake in various tissues. Time–activity curves
(TACs) were generated from the ROI analysis on dynamic PET/CT data using 20 s frames. CT images
were recorded using an X-ray current of 300 µA, 360 projections, and an image size of 63.8 mm ×
63.8 mm × 46.0 mm. Data were acquired using the Vista CT 4.11 Build 701 software, and reconstructed
images were analyzed by using ASIPro VMTM software (Concorde Microsystems, Siemens Preclinical
Solutions, LLC, Knoxville, TN, USA) and VivoQuant® 1.23 (InviCRO, LLC, Boston, MA, USA).
3.2. Data Analysis and Statistics
Data and statistical analyses were performed using GraphPad Prism 5.01 (GraphPad Software,
Inc., La Jolla, CA, USA) and Microsoft Excel spreadsheets. Differences at the 95% confidence level
(p < 0.05) were considered to be statistically significant.
Supplementary Materials: The following are available online, Figures S1–S3 Semi-preparative HPLC traces of a
typical radiosynthesis of [18F]FPEB using precursor (5–7).
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